How do I read a peptide lab report?
A peptide Certificate of Analysis (COA) or lab report documents identity and purity through standardized analytical measurements. Key fields include sample batch number (for traceability), purity percentage by reverse-phase HPLC at 214 nm (typically 85–99%), molecular mass confirmed by LC-MS, amino acid composition, the analytical method name and date of analysis, and recommended storage conditions for maintaining sample quality.
5Minimum analytical techniques for comprehensive peptide identity confirmation
Sample Identification and Batch Information
The report header identifies the sample by name (peptide sequence or common name), batch number, lot number, and analysis date. The batch and lot numbers allow traceability to the synthesis run and manufacturing date; reports documenting the same physical sample should cite identical numbers. The analysis date defines when the purity percentage is valid. A COA from 6 months ago does not reflect current purity if the sample has been stored improperly. The report header should also specify the counter-ion form (acetate, TFA, hydrochloride) because different forms have different molar masses[1][2].
Some reports include laboratory accreditation (ISO 9001, ISO/IEC 17025), analyst signature, and reference to validated standard operating procedures. These indicate quality assurance. The report should specify whether analysis was performed for regulatory compliance, analytical standards, or research use only. This determines the stringency of the testing: pharmaceutical-grade analysis requires more extensive validation and documentation than research-grade analysis[3][4].
HPLC Purity Results and Chromatographic Data
The HPLC section reports purity as a percentage: (target peak area) / (sum of all peak areas) × 100%. The detection wavelength (typically 214 nm for all peptides, measuring peptide bond absorption) is specified. A well-formatted report includes the chromatogram image showing peaks and their retention times (e.g., "target peptide at 12.3 minutes"). Visual inspection of the chromatogram reveals peak quality: one large peak indicates high purity; multiple similar-sized peaks indicate incomplete purification or degradation during synthesis. The method section specifies column type (C18, C8), column dimensions and particle size, mobile phase composition (water-acetonitrile gradient with acidic modifiers), flow rate (mL/min), and column temperature (°C)[1][5].
Purity results typically range from 85–99% for synthetic peptides. Results below 90% suggest incomplete purification or degradation during storage; results above 98% suggest very high synthetic yield or may indicate that trace impurities are below the detection limit of the method. The method details allow assessment of accuracy and reproducibility: if methods differ between reports (different columns, temperatures, or gradient programs), purity differences may reflect analytical method variation rather than actual product quality differences. High-quality reports include the actual chromatogram trace image, not just a purity percentage number, allowing visual inspection of peak separation quality[2][8].
Molecular Mass and LC-MS Confirmation
The mass spectrometry section confirms the molecular mass of the target peptide. The report lists the observed mass and theoretical mass (calculated from amino acid composition). For a 2000 Da peptide, observed and theoretical values should match within ±0.1% accuracy. Electrospray ionization (ESI) reports m/z (mass-to-charge ratio); a singly protonated peptide (M+H)+ appears at m/z ~ (mass + 1) Daltons. The ionization method is specified (ESI, MALDI, or other)[7][6].
LC-MS/MS (tandem mass spectrometry) provides sequence confirmation by fragmenting the peptide and measuring fragment masses. Fragment patterns are specific to the amino acid sequence, so they confirm identity beyond mass alone. Amino acid analysis (acid hydrolysis followed by quantification) measures the total molar amount of each amino acid, allowing independent confirmation of composition. A comprehensive report includes both mass and sequence-level confirmation, providing highest confidence in identity[4][8].
Method Documentation and Analytical Standards
A complete report includes full analytical method details: column dimensions and particle size, mobile phase composition (e.g., "0.1% formic acid in water and acetonitrile"), gradient program (initial and final organic concentration, duration), flow rate (mL/min), column temperature (°C), and detection wavelength (nm). Without these details, purity results cannot be compared between laboratories or reproduced. The report should reference whether the method is validated (per ICH Q2 guidelines) and include documentation of method validation studies[1][3].
The report should specify analyst name or initials, date of analysis, and any reference standards used. If the analysis cites an external standard (e.g., "purity confirmed against USP or pharmacopeial standard"), it indicates quality assurance. Reports for regulatory submissions or critical applications typically include evidence of method validation: accuracy tests (comparing reported purity to true purity), precision tests (repeatability), and linearity tests (response proportional to concentration)[5][9].
Impurity Profile and Storage Guidance
A comprehensive report identifies major impurities by name and percentage. For example: "N-terminal truncated variant: 2.5%; oxidized methionine: 1.2%; water: 1.3%". If impurities are not named, they are below detection limits (<0.5% each) or not individually resolved. Identifying impurities allows assessment of whether they could interfere with the intended application. If major impurity peaks are not explained, request clarification from the laboratory[1][5].
The report should include recommended storage conditions (e.g., "-20°C, sealed, desiccated") and an estimated shelf life (e.g., "24 months at -20°C"). These reflect expected peptide stability under standard conditions. Proper storage from the analysis date onward is required to maintain the reported purity. The absence of storage guidance does not imply the peptide is stable at room temperature; assume freezing and desiccation are necessary unless otherwise stated[4][10].
| Study | Result | Ref |
|---|---|---|
| Sample ID, batch number, date of analysis | Identifies sample for traceability; analysis date defines when purity is valid | [1] |
| HPLC purity percentage and chromatogram | Purity typically 85–99%; visual chromatogram shows peak quality and retention time | [2] |
| Molecular mass by LC-MS or MALDI-TOF | Observed mass matches theoretical mass within ±0.1%; confirms target peptide present | [7] |
| LC-MS/MS sequence confirmation or amino acid analysis | Confirms amino acid sequence or composition; detects truncations and misincorporations | [4] |
| Complete analytical method (column, mobile phase, gradient, temperature) | Describes exact conditions used for analysis; enables method comparison and reproduction | [3] |
| Storage conditions and shelf life recommendation | Specifies storage temperature, protection from light/moisture; estimated stability duration | [10] |
Frequently asked questions
What does the purity percentage on a lab report represent?
Purity percentage is measured by HPLC as: (area of target peptide peak) / (total area of all peaks) × 100%. A 95% result means 95% of the measured material is the target peptide; 5% is impurities (synthesis byproducts, truncated sequences, oxidized variants, residual salts). This method assumes all compounds absorb equally at 214 nm, which is approximately true for peptides. Salts and non-peptide compounds that do not absorb at 214 nm are invisible and do not contribute to the denominator.
Why do I need both HPLC purity and mass spectrometry results?
HPLC measures purity (the percentage of target compound) but does not directly confirm chemical identity. Two different peptides could have similar retention times and appear as one peak. Mass spectrometry measures the exact molecular mass, confirming that the peak is the intended peptide. Together, HPLC + mass spectrometry provide both purity and identity confirmation. LC-MS/MS fragmentation patterns add sequence-level confirmation, providing the highest level of structural certainty.
How can I tell if a lab report is complete and reliable?
A complete report includes: (1) sample identification and batch number, (2) HPLC purity with method details and chromatogram image, (3) molecular mass by LC-MS or MALDI-TOF, (4) amino acid analysis or sequence confirmation by LC-MS/MS, (5) complete analytical method documentation (column, mobile phase, gradient, temperature, detection wavelength), (6) impurity identification (not just a single purity %), (7) analyst name/signature and analysis date, and (8) storage recommendations and shelf life. Reports lacking method details or impurity identification are incomplete.
What should I do if purity differs between two lab reports?
First, check if the methods are identical: different HPLC columns, gradient programs, or detection wavelengths can produce different purity values for the same sample. Request method documentation from both laboratories and compare. If methods differ, the different purity values may reflect analytical method variation rather than product quality difference. To make fair comparisons, request identical methods or re-analysis of both samples by a single reference laboratory using standardized conditions.
How old can a lab report be and still be reliable?
A lab report is only reliable if the sample has been stored properly since the analysis date. A 1-year-old report for a peptide stored frozen, sealed, and desiccated remains valid. A 1-month-old report for a peptide stored at room temperature or exposed to light and humidity may be invalid because degradation can occur. Proper storage from analysis date forward is critical. If the storage history is unknown, request re-analysis to confirm current purity, or store the peptide properly going forward.
References
- High-Performance Reversed-Phase Flash Chromatography Purification of Peptides and Chemically Modified Insulins. Chembiochem : a European journal of chemical biology. 2021. PMID 33443297
- Synthetic pharmaceutical peptides characterization by chromatography principles and method development. Journal of separation science. 2022. PMID 35460196
- Reprint of "Mixed-mode chromatography in pharmaceutical and biopharmaceutical applications". Journal of pharmaceutical and biomedical analysis. 2016. PMID 27645457
- Comprehensive multi-attribute method workflow for biotherapeutic characterization and current good manufacturing practices testing. Nature protocols. 2023. PMID 36526726
- Purification of a peptide tagged protein via an affinity chromatographic process with underivatized silica. Engineering in life sciences. 2021. PMID 34690628
- Automated multi-attribute method sample preparation using high-throughput buffer exchange tips. Rapid communications in mass spectrometry : RCM. 2022. PMID 34783086
- A combination of multiple LC-MS approaches for the comprehensive characterization of cysteine-linked ADCs. Journal of pharmaceutical and biomedical analysis. 2024. PMID 38968868
- Comprehensive UHPLC- and CE-based methods for engineered Cas9 characterization. Talanta. 2023. PMID 35988299
- Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests. Analytical and bioanalytical chemistry. 2015. PMID 25410642
- Expression, purification, and characterization of the Degludec precursor DesB30. Protein expression and purification. 2019. PMID 31039402
RUO For laboratory research use only. Not for human or veterinary use. This page summarises published studies and is not medical advice.